Understanding how TAZ affects the tumor environment in aggressive breast cancer
TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast Cancer
['FUNDING_R03'] · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · NIH-10995290
This study is looking at a protein called TAZ to see how it affects the immune system and tumor growth in triple-negative breast cancer, with the hope of finding new treatment options for patients facing this challenging type of cancer.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS (nih funded) |
| Locations | 1 site (TOLEDO, UNITED STATES) |
| Trial ID | NIH-10995290 on ClinicalTrials.gov |
What this research studies
This research investigates the role of TAZ, a protein involved in cell signaling, in the tumor microenvironment of triple-negative breast cancer (TNBC). The study aims to understand how TAZ influences the behavior of immune cells and tumor progression, particularly in the context of TNBC, which is known for its aggressive nature and lack of targeted therapies. By using mouse models, researchers will explore how TAZ expression impacts the recruitment and function of immune suppressive cells that can affect tumor growth and response to treatment. This could lead to new insights into potential therapeutic strategies for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer.
Not a fit: Patients with other subtypes of breast cancer or those who do not have breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promising results in understanding the role of immune cells in cancer progression, suggesting that this approach could yield valuable insights.
Where this research is happening
TOLEDO, UNITED STATES
- UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS — TOLEDO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, JIANMIN — UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS
- Study coordinator: ZHANG, JIANMIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.